Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)

Market Cap	552.56M -47.5%
Revenue (ttm)	50.00M
Net Income	-77.96M
EPS	-0.32
Shares Out	243.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,400
Open	2.200
Previous Close	2.200
Day's Range	2.120 - 2.310
52-Week Range	1.820 - 10.770
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About HKG:2185

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated ba...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 65
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2185

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error